Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified vero cells induce robust protection

Journal of Virology

Volumn 83, Issue 10, 2009, Pages 5192-5203

  Mayrhofer, Josef ^a   Coulibaly, Sogue ^a   Hessel, Annett ^a   Holzer, Georg W ^a   Schwendinger, Michael ^a   Brühl, Peter ^a   Gerencer, Marijan ^a   Crowe, Brian A ^a   Shuo, Shen ^b   Hong, Wanjing ^b   Yee, Joo Tan ^b   Dietrich, Barbara ^a   Sabarth, Nicolas ^a   Savidis Dacho, Helga ^a   Kistner, Otfried ^a   Barrett, P Noel ^a   Falkner, Falko G ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; GAMMA INTERFERON; HEMAGGLUTININ; INFLUENZA VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS VECTOR; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; HUMORAL IMMUNITY; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PANDEMIC; POXVIRUS; PRIORITY JOURNAL; VACCINE PRODUCTION; VACCINIA VIRUS; VERO CELL; VIRULENCE; VIRUS INACTIVATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CERCOPITHECUS; DEFECTIVE VIRUS; FEMALE; GENE VECTOR; GENETICS; IMMUNOLOGY; NUDE MOUSE; ORTHOMYXOVIRUS INFECTION; VIRUS CULTURE;

AVIAN INFLUENZA VIRUS; MUS; ORTHOMYXOVIRIDAE; POXVIRIDAE; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; DEFECTIVE VIRUSES; FEMALE; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, NUDE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINIA VIRUS; VERO CELLS; VIRUS CULTIVATION;

EID: 65349108007     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02081-08     Document Type: Article

References (51)

1. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
2. Belyakov, I. M., B. Moss, W. Strober, and J. A. Berzofsky. 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. USA 96:4512-4517.
3. Carroll, M. W., and B. Moss. 1997. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238:198-211.
4. Cooney, E. L., A. C. Collier, P. D. Greenberg, R. W. Coombs, J. Zarling, D. E. Arditti, M. C. Hoffman, S. L. Hu, and L. Corey. 1991. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337:567-572.
5. De, B. K., M. W. Shaw, P. A. Rota, M. W. Harmon, J. J. Esposito, R. Rott, N. J. Cox, and A. P. Kendal. 1988. Protection against virulent H5 avian influenza virus infection in chickens by an inactivated vaccine produced with recombinant vaccinia virus. Vaccine 6:257-261.
6. Drexler, I., K. Heller, B. Wahren, V. Erfle, and G. Sutter. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:347-352.
7. Ehrlich, H. J., M. Muller, H. M. Oh, P. A. Tambyah, C. Joukhadar, E. Montomoli, D. Fisher, G. Berezuk, S. Fritsch, A. Low-Baselli, N. Vartian, R. Bobrovsky, B. G. Pavlova, E. M. Pollabauer, O. Kistner, and P. N. Barrett. 2008. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358:2573-2584.
8. Emeny, J. M., and M. J. Morgan. 1979. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J. Gen. Virol. 43:247-252.
9. Fodor, E., L. Devenish, O. G. Engelhardt, P. Palese, G. G. Brownlee, and A. Garcia-Sastre. 1999. Rescue of influenza A virus from recombinant DNA. J. Virol. 73:9679-9682. (Pubitemid 29487131)
10. Gasteiger, G., W. Kastenmuller, R. Ljapoci, G. Sutter, and I. Drexler. 2007. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J. Virol. 81:11925-11936. (Pubitemid 47623824)
11. Graham, F. L. 2000. Adenovirus vectors for high-efficiency gene transfer into mammalian cells. Immunol. Today 21:426-428.
12. Hermans, I. F., J. D. Silk, J. Yang, M. J. Palmowski, U. Gileadi, C. McCarthy, M. Salio, F. Ronchese, and V. Cerundolo. 2004. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J. Immunol. Methods 285:25-40.
13. Hoelscher, M. A., S. Garg, D. S. Bangari, J. A. Belser, X. Lu, I. Stephenson, R. A. Bright, J. M. Katz, S. K. Mittal, and S. Sambhara. 2006. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367:475-481.
14. Hoelscher, M. A., L. Jayashankar, S. Garg, V. Veguilla, X. Lu, N. Singh, J. M. Katz, S. K. Mittal, and S. Sambhara. 2007. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin. Pharmacol. Ther. 82:665-671.
15. Holzer, G. W., and F. G. Falkner. 1997. Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line. J. Virol. 71:4997-5002. (Pubitemid 27258169)
16. Holzer, G. W., W. Gritschenberger, J. A. Mayrhofer, V. Wieser, F. Dorner, and F. G. Falkner. 1998. Dominant host range selection of vaccinia recombinants by rescue of an essential gene. Virology 249:160-166.
17. Holzer, G. W., J. Mayrhofer, W. Gritschenberger, and F. G. Falkner. 2005. Dominant negative selection of vaccinia virus using a thymidine kinase/ thymidylate kinase fusion gene and the prodrug azidothymidine. Virology 337:235-241.
18. Horimoto, T., and Y. Kawaoka. 2005. Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3:591-600.
19. Kanesa-thasan, N., J. J. Smucny, C. H. Hoke, D. H. Marks, E. Konishi, I. Kurane, D. B. Tang, D. W. Vaughn, P. W. Mason, and R. E. Shope. 2000. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19:483-491.
20. Kistner, O., P. N. Barrett, W. Mundt, M. Reiter, S. Schober-Bendixen, G. Eder, and F. Dorner. 1999. Development of a Vero cell-derived influenza whole virus vaccine. Dev. Biol. Stand. 98:101-110.
21. Kistner, O., M. K. Howard, M. Spruth, W. Wodal, P. Bruhl, M. Gerencer, B. A. Crowe, H. Savidis-Dacho, I. Livey, M. Reiter, I. Mayerhofer, C. Tauer, L. Grillberger, W. Mundt, F. G. Falkner, and P. N. Barrett. 2007. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25:6028-6036.
22. Kreijtz, J. H., Y. Suezer, G. van Amerongen, G. de Mutsert, B. S. Schnierle, J. M. Wood, T. Kuiken, R. A. Fouchier, J. Lower, A. D. Osterhaus, G. Sutter, and G. F. Rimmelzwaan. 2007. Recombinant modified vaccinia virus Ankarabased vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 195:1598-1606. (Pubitemid 46799217)
23. Larsson, M., J. F. Fonteneau, S. Somersan, C. Sanders, K. Bickham, E. K. Thomas, K. Mahnke, and N. Bhardwaj. 2001. Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur. J. Immunol. 31:3432-3442. (Pubitemid 34030955)
24. Levenbook, I., P. L. Smith, and J. C. Petricciani. 1981. A comparison of three routes of inoculation for testing tumorigenicity of cell lines in nude mice. J. Biol. Stand. 9:75-80. (Pubitemid 11187213)
25. Levenbook, I. S., J. C. Petricciani, and B. L. Elisberg. 1984. Tumorigenicity of Vero cells. J. Biol. Stand. 12:391-398. (Pubitemid 15119429)
26. Lipatov, A. S., E. A. Govorkova, R. J. Webby, H. Ozaki, M. Peiris, Y. Guan, L. Poon, and R. G. Webster. 2004. Influenza: emergence and control. J. Virol. 78:8951-8959.
27. Lu, X., T. M. Tumpey, T. Morken, S. R. Zaki, N. J. Cox, and J. M. Katz. 1999. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J. Virol. 73:5903-5911. (Pubitemid 29274877)
28. McCarthy, K., C. H. Taylor-Robinson, and S. E. Pillinger. 1963. Isolation of Rubella virus from cases in Britain. Lancet ii:593-598.
29. Miller, A. D., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. BioTechniques 7:980-990.
30. Monath, T. P., J. R. Caldwell, W. Mundt, J. Fusco, C. S. Johnson, M. Buller, J. Liu, B. Gardner, G. Downing, P. S. Blum, T. Kemp, R. Nichols, and R. Weltzin. 2004. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)-a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 8(Suppl. 2):S31-S44. (Pubitemid 39445966)
31. Neumann, G., T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D. R. Perez, R. Donis, E. Hoffmann, G. Hobom, and Y. Kawaoka. 1999. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 96:9345-9350.
32. Nicolson, C., D. Major, J. M. Wood, and J. S. Robertson. 2005. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23:2943-2952.
33. Ober, B. T., P. Bruhl, M. Schmidt, V. Wieser, W. Gritschenberger, S. Coulibaly, H. Savidis-Dacho, M. Gerencer, and F. G. Falkner. 2002. Immunogenicity and safety of defective vaccinia virus Lister: comparison with modified vaccinia virus Ankara. J. Virol. 76:7713-7723.
34. Obst, R., H. M. van Santen, R. Melamed, A. O. Kamphorst, C. Benoist, and D. Mathis. 2007. Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation. Proc. Natl. Acad. Sci. USA 104:15460-15465.
35. Orr, N., M. Forman, H. Marcus, S. Lustig, N. Paran, I. Grotto, E. Klement, Y. Yehezkelli, G. Robin, S. Reuveny, A. Shafferman, and D. Cohen. 2004. Clinical and immune responses after revaccination of Israeli adults with the Lister strain of vaccinia virus. J. Infect. Dis. 190:1295-1302. (Pubitemid 39287757)
36. Oseroff, C., F. Kos, H. H. Bui, B. Peters, V. Pasquetto, J. Glenn, T. Palmore, J. Sidney, D. C. Tscharke, J. R. Bennink, S. Southwood, H. M. Grey, J. W. Yewdell, and A. Sette. 2005. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc. Natl. Acad. Sci. USA 102:13980-13985.
37. Palese, P., and A. Garcia-Sastre. 2002. Influenza vaccines: present and future. J. Clin. Investig. 110:9-13.
38. Plotkin, S. A., A. Murdin, and E. Vidor. 1999. Inactivated polio vaccine, p. 345-363. In S. A. Plotkin and W. A. Orenstein (ed.), Vaccines, 3rd ed. W. B. Saunders, Philadelphia, PA.
39. Ramirez, J. C., M. M. Gherardi, D. Rodriguez, and M. Esteban. 2000. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol. 74:7651-7655. (Pubitemid 30613113)
40. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
41. Rubinstein, S., and M. Schoofs. 2007. Canceled vaccine may have boosted HIBV risk. Wall Street J. http://online.wsj.com/article/SB119445916050785399. html.
42. Sheets, R. 2000. History and characterization of the Vero cell line. Report prepared for the Vaccines and Related Biological Products Advisory Committee Meeting. FDA, Rockville, MD. http://www.fda.gov/ohrms/dockets/AC/00/ backgrd/3616b1a.pdf.
43. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89:10847-10851.
44. Sutter, G., L. S. Wyatt, P. L. Foley, J. R. Bennink, and B. Moss. 1994. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:1032-1040.
45. + T-cell determinants and cross-reactivity in BALB/c mice. J. Virol. 80:6318-6323.
46. Veits, J., A. Romer-Oberdorfer, D. Helferich, M. Durban, Y. Suezer, G. Sutter, and T. C. Mettenleiter. 2008. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 26:1688-1696.
47. Wyatt, L. S., P. L. Earl, J. Vogt, L. A. Eller, D. Chandran, J. Liu, H. L. Robinson, and B. Moss. 2008. Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 26:486-493.
48. Wyatt, L. S., S. T. Shors, B. R. Murphy, and B. Moss. 1996. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14:1451-1458.
49. Yamada, S., Y. Suzuki, T. Suzuki, M. Q. Le, C. A. Nidom, Y. Sakai-Tagawa, Y. Muramoto, M. Ito, M. Kiso, T. Horimoto, K. Shinya, T. Sawada, M. Kiso, T. Usui, T. Murata, Y. Lin, A. Hay, L. F. Haire, D. J. Stevens, R. J. Russell, S. J. Gamblin, J. J. Skehel, and Y. Kawaoka. 2006. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444:378-382.
50. Yap, K. L., and G. L. Ada. 1978. The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen. Scand. J. Immunol. 8:413-420.
51. Yuen, L., and B. Moss. 1987. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc. Natl. Acad. Sci. USA 84:6417-6421.